AGC

News Release

AGC Signs Agreement for Acquisition of a Leading Biopharmaceutical CDMO, CMC Biologics

Tokyo, December 20, 2016—AGC Asahi Glass ("AGC"), a world-leading manufacturer of glass, chemicals and high-tech materials, announces that it has entered into an agreement to acquire 100% of the shares of CMC Biologics ("CMC"), a world-leading biologics Active Pharmaceutical Ingredients ("API") manufacturer with major investors including Monitor Clipper Partners and European Equity Partners, for a purchase price of approximately 60 billion Japanese yen. The agreement remains subject to approval from the relevant antitrust authority, and the acquisition is expected to be completed in January 2017.

CMC is a Contract Development and Manufacturing Organization ("CDMO"), offering biological API manufacturing service with mammalian and microbial hosts. The company provides high value-added cell line construction, process development, scale-up and manufacturing of API used in drug development (pre-clinical and clinical trials) and in commercially marketed biopharmaceutical drugs. With approximately 530 employees, CMC operates on a global scale with production facilities in Denmark (Copenhagen) and USA (Seattle and Berkeley).

David Kauffmann, Chairman of CMC Biologics said "I am excited by CMC Biologics becoming part of AGC a world-class company committed to excellence and high customer satisfaction. AGC's dedication to best technology solutions and long-time partnership with clients align so well with CMC Biologics' quest to be the preferred biologics CDMO service partner for the world's top pharmaceutical and biotech companies"

"We are honored to become part of AGC, a successful global company with a long term business strategy and resources to be the ideal owner of CMC Biologics. The CMC management team look forward to becoming one team with AGC, to bring and combine broad, as well as focused innovative solutions to our clients said Gustavo Mahler, President & Chief Executive Officer of CMC Biologics and added, "With this transaction, I am confident that our clients will receive even further benefits from our combined high level of expertise, years of experience, and global offerings."

AGC has been engaged in contract manufacturing business since the early 2000s. Its acquisition of CMC is part of AGC's strategy to expand its biologics CDMO operations, complementing AGC's current operations in Japan and Europe*note. The business integration with CMC will enable AGC to offer world-leading biologics CDMO API services, with a host of best-in-class technologies and manufacturing solutions by both mammalian and microbial operations for its global customer base.

Under its management policy, AGC plus, the AGC Group has designated its Life Science Business as one of its strategic areas. Through the business integration, the AGC Group will accelerate and expand its biopharmaceutical contract services business around the world.

*AGC's European operations made a full-fledged start through the acquisition of a German CDMO Biomeva in August this year. Please refer to AGC's press release at: http://www.agc.com/english/news/20160906e.pdf

<Media inquiries>

Junichi Kobayashi, General Manager, Corporate Communications & Investor Relations Office

AGC Asahi Glass

(Contact: Tomoko Komazaki; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)



News Release

<Reference>

Profile of CMC Biologics

Company: CMC biologics
Representative: Gustavo Mahler

Locations: Denmark (Copenhagen) and USA (Seattle and Berkeley)

Established: 2001

Business Description: A global contract process development and manufacturer of biopharmaceuticals

About the AGC Group

AGC Asahi Glass (or also called AGC, Registered Company name: Asahi Glass Co., Ltd., Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.3 trillion Japanese yen through business in about 30 countries. For more information, please visit www.agc-group.com.